Phaseline

Companies › Medtronic Spinal and Biologics

Medtronic Spinal and Biologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MDT-0123
Spine cage combination product for intervertebral fusion and spinal stabilization
–Phase 3Disc DegenerationMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07414745MDT-0123Phase 3Disc DegenerationOtherMar 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma Vertanical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.